XTL Biopharmaceuticals Ltd completed the acquisition of an 83.4% stake in Psyga Bio Ltd., marking a strategic expansion into psychedelic and functional mushroom-derived therapeutics. This complements its legacy autoimmune disease assets like the synthetic peptide hCDR1, sublicensed to Biossil Inc. Despite enhancing its pipeline with clinically advanced candidates and GMP manufacturing capabilities, XTL faces persistent liquidity constraints and negative cash flows, raising substantial doubt about its ability to continue as a going concern without additional capital. The liquidation of its prior data analytics subsidiary, The Social Proxy Ltd., has narrowed focus back to core biotech development and milestone-dependent royalty models.